JP2012525432A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012525432A5 JP2012525432A5 JP2012508753A JP2012508753A JP2012525432A5 JP 2012525432 A5 JP2012525432 A5 JP 2012525432A5 JP 2012508753 A JP2012508753 A JP 2012508753A JP 2012508753 A JP2012508753 A JP 2012508753A JP 2012525432 A5 JP2012525432 A5 JP 2012525432A5
- Authority
- JP
- Japan
- Prior art keywords
- her3
- antibody
- heregulin
- binds
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17367009P | 2009-04-29 | 2009-04-29 | |
| US61/173,670 | 2009-04-29 | ||
| PCT/US2010/033058 WO2010127181A1 (en) | 2009-04-29 | 2010-04-29 | Improved antibodies immunoreactive with heregulin-coupled her3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012525432A JP2012525432A (ja) | 2012-10-22 |
| JP2012525432A5 true JP2012525432A5 (https=) | 2013-05-30 |
Family
ID=43032570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012508753A Pending JP2012525432A (ja) | 2009-04-29 | 2010-04-29 | ヘレグリン共役型ｈｅｒ３と免疫反応性の改善された抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US8362215B2 (https=) |
| EP (1) | EP2425009A4 (https=) |
| JP (1) | JP2012525432A (https=) |
| AU (1) | AU2010242914B2 (https=) |
| CA (1) | CA2759792A1 (https=) |
| IL (1) | IL216014A0 (https=) |
| WO (1) | WO2010127181A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA33892B1 (fr) | 2009-12-22 | 2013-01-02 | Roche Glycart Ag | Anticorps anti-her3, et leurs utilisations |
| CN102884085B (zh) | 2010-04-09 | 2016-08-03 | Aveo制药公司 | 抗erbb3抗体 |
| NZ607337A (en) | 2010-08-20 | 2015-06-26 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
| TW201302793A (zh) * | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| JP6033783B2 (ja) | 2010-11-01 | 2016-11-30 | シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ | Ｐａｎ−ｈｅｒ抗体組成物 |
| US20140134170A1 (en) | 2011-03-11 | 2014-05-15 | Merrimack Pharmaceuticals, Inc. | Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers |
| SG192775A1 (en) | 2011-03-15 | 2013-09-30 | Merrimack Pharmaceuticals Inc | Overcoming resistance to erbb pathway inhibitors |
| CN105884900A (zh) | 2011-04-19 | 2016-08-24 | 梅里麦克制药股份有限公司 | 单特异性和双特异性抗igf-1r和抗erbb3抗体 |
| KR102101806B1 (ko) * | 2011-05-19 | 2020-04-20 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 항-인간-her3 항체 및 이의 용도 |
| US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
| HK1200468A1 (en) | 2011-09-30 | 2015-08-07 | Regeneron Pharmaceuticals, Inc. | Anti-erbb3 antibodies and uses thereof |
| US9828635B2 (en) | 2011-10-06 | 2017-11-28 | Aveo Pharmaceuticals, Inc. | Predicting tumor response to anti-ERBB3 antibodies |
| JP6180425B2 (ja) | 2011-11-23 | 2017-08-23 | メディミューン，エルエルシー | Ｈｅｒ３に特異的な結合分子及びそれらの使用 |
| KR20140103135A (ko) * | 2011-12-05 | 2014-08-25 | 노파르티스 아게 | Her3의 도메인 ii에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체 |
| EA201491120A1 (ru) * | 2011-12-05 | 2015-07-30 | Новартис Аг | Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен iii и домен iv her3 |
| AU2012349735B2 (en) | 2011-12-05 | 2016-05-19 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (HER3) |
| US9725511B2 (en) | 2012-11-08 | 2017-08-08 | Hoffmann-La Roche Inc. | Anti-HER3/HER4 antibodies binding to the beta-hairpin of HER3 and the beta-hairpin of HER4 |
| MX2015005757A (es) | 2012-11-08 | 2015-11-18 | Hoffmann La Roche | Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3. |
| US9180185B2 (en) | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
| JP6357113B2 (ja) * | 2013-02-08 | 2018-07-11 | 株式会社医学生物学研究所 | ヒトｎｒｇ１タンパク質に対する抗体 |
| EP2821071A1 (en) | 2013-07-04 | 2015-01-07 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Compounds for breast cancer treatment |
| US11305012B2 (en) | 2013-09-24 | 2022-04-19 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
| WO2015066543A1 (en) * | 2013-11-01 | 2015-05-07 | Board Of Regents, The University Of Texas System | Targeting her2 and her3 with bispecific antibodies in cancerous cells |
| EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| US10745490B2 (en) | 2014-04-11 | 2020-08-18 | Celldex Therapeutics, Inc. | Anti-ErbB antibodies and methods of use thereof |
| MX2016014416A (es) | 2014-05-14 | 2017-02-23 | Hoffmann La Roche | Anticuerpos anti-her3 que se unen a la horquilla beta de her3. |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| JP2018536682A (ja) | 2015-12-11 | 2018-12-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｅｇｆｒ及び／またはｅｒｂｂ３遮断に耐性のある腫瘍の成長を低減または防止するための方法 |
| WO2019185164A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5183884A (en) * | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| US5968511A (en) * | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| CA2257839C (en) * | 1996-07-12 | 2012-10-23 | Genentech, Inc. | Gamma-heregulin |
| US20090087878A9 (en) * | 1999-05-06 | 2009-04-02 | La Rosa Thomas J | Nucleic acid molecules associated with plants |
| US7125680B2 (en) * | 2001-07-27 | 2006-10-24 | The Regents Of The University Of California | Methods and materials for characterizing and modulating interaction between heregulin and HER3 |
| EP1283053A1 (en) * | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| US20040028685A1 (en) * | 2002-05-10 | 2004-02-12 | Kinch Michael S. | EphA2 monoclonal antibodies and methods of use thereof |
| US7501494B2 (en) * | 2003-01-15 | 2009-03-10 | United Biomedical, Inc. | Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection |
| WO2005040339A2 (en) * | 2003-07-18 | 2005-05-06 | The Regents Of The University Of California | Aptamers to human epidermal growth factor receptor-3 |
| US7413868B2 (en) | 2003-11-05 | 2008-08-19 | Trellis Bioscience, Inc. | Use of particulate labels in bioanalyte detection methods |
| EP3190125A1 (en) * | 2005-08-31 | 2017-07-12 | Merck Sharp & Dohme Corp. | Engineered anti-il-23 antibodies |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
-
2010
- 2010-04-29 AU AU2010242914A patent/AU2010242914B2/en not_active Ceased
- 2010-04-29 JP JP2012508753A patent/JP2012525432A/ja active Pending
- 2010-04-29 EP EP10770384A patent/EP2425009A4/en not_active Ceased
- 2010-04-29 US US12/770,674 patent/US8362215B2/en not_active Expired - Fee Related
- 2010-04-29 CA CA2759792A patent/CA2759792A1/en not_active Abandoned
- 2010-04-29 WO PCT/US2010/033058 patent/WO2010127181A1/en not_active Ceased
-
2011
- 2011-10-27 IL IL216014A patent/IL216014A0/en unknown
-
2013
- 2013-01-17 US US13/744,299 patent/US8828388B2/en not_active Expired - Fee Related
-
2014
- 2014-09-02 US US14/475,348 patent/US9321839B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012525432A5 (https=) | ||
| ES2595091T3 (es) | Composiciones farmacéuticas con resistencia a CEA soluble | |
| JP2008529489A5 (https=) | ||
| Friedländer et al. | ErbB-directed immunotherapy: antibodies in current practice and promising new agents | |
| JP2012523848A5 (https=) | ||
| TW200639181A (en) | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof | |
| WO2008017963A3 (en) | Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof | |
| CA2749846A1 (en) | Methods of determining patient response by measurement of her-3 | |
| JP2008538289A5 (https=) | ||
| JP2008508903A5 (https=) | ||
| JP2020534830A5 (https=) | ||
| JP2013506428A5 (https=) | ||
| PH12012502376A1 (en) | Modified antigen binding molecules with altered cell signaling activity | |
| JP2012515226A5 (https=) | ||
| JP2016500655A5 (https=) | ||
| JP2008520186A5 (https=) | ||
| JP2019507762A5 (https=) | ||
| JP2019535763A5 (https=) | ||
| JP2017519501A5 (https=) | ||
| IL212056A0 (en) | Monoclonal antibodies and methods for their use in the detection of cervical disease | |
| JP2013527761A5 (https=) | ||
| NZ597067A (en) | Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer | |
| TNSN06126A1 (en) | Antigen binding molecules with increased fc receptor binding affinity and effector function | |
| JP2017526339A5 (https=) | ||
| JP2009545325A5 (https=) |